The 2018/19 Ebola epidemic the Democratic Republic of the Congo (DRC): epidemiology, outbreak control, and conflict.

The Democratic Republic of Congo (DRC) (formerly Zaire) was the location of the first Ebola outbreak, in 1976, and since then there have been a total of ten outbreaks in different parts of the country. The current outbreak, the first in eastern DRC (North Kivu and Ituri provinces), began in July 2018, and by December 2019, there had been 3262 cases and 2232 deaths. Within weeks of the first reported cases, the World Health Organisation (WHO) and the DRC Ministry of Health (MOH) initiated a major response programme, with laboratory support, international agencies providing personnel, and material resources. Unlike previous Ebola outbreaks, including the west Africa epidemic, a proven vaccine, and trial therapeutic agents have been available as part of the outbreak response. Two therapeutic agents, mAb114 and REGN-EB3, both monoclonal antibody derived, have shown case fatality rates (CFR) of around 30%, compared to the overall of 66%. Despite these positive interventions, the outbreak has continued for eighteen months. Underlying the outbreak response has been a high number of violent incidents by local militias, and community mistrust and lack of involvement that has hampered many aspects of the response programme. As a result, many cases are not reported early and not transferred to treatment centres, deaths and increased transmission occur in the community, and the response programme is reaching only a proportion of the cases. New strategies to improve community participation, and integrate the Ebola response into the existing health structure are planned to improve the programme effectiveness.

Antimicrobial susceptibility pattern of extended spectrum beta-lactamase producing gram-negative bacteria isolated from wound and urine in a tertiary care hospital, Dhaka City, Bangladesh.

From a total of 320 bacterial samples from wound swab and urine 169 (53%) gram-negative bacteria were isolated, of which 42 (25%) extended-spectrum beta-lactamase (ESBL) producers were detected by double-disk synergy test. ESBL producers were significantly more resistant against amoxiclav, Co-trimoxazole, ciprofloxacin, amikacin and gentamicin than non-ESBL producers. Among the 42 ESBL producers, 76% were positive for blaCTX-M and 43% were positive for blaOXA, with blaCTX-M predominantly (97%) observed in E. coli and blaOXA predominantly (80%) in Pseudomonas spp. Class 1 integron was found in 75% of blaCTX-M positive and 56% of blaOXA positive strains. Combinations of ESBL genes and class 1 integron were observed in 29 (69%) of the ESBL producers. The findings of this study infer that CTX-M and OXA producers are emerging in Bangladesh and we report the presence of blaOXA for the first time in Bangladesh.

Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis.

The association between severe bronchiolitis and dual infection by human metapneumovirus (hMPV) and human respiratory syncytial virus (hRSV) was investigated in <2-year-old infants with bronchiolitis who were admitted to the hospital during the 2001-2002 winter season. hMPV in nasopharyngeal aspirate and/or cells and fluid collected by nonbronchoscopic bronchoalveolar lavage was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). hRSV was detected in nasopharyngeal aspirate and/or cells and fluid collected by nonbronchoscopic bronchoalveolar lavage by enzyme immunoassay, tissue culture, and RT-PCR. Dual infection with hMPV and hRSV confers a 10-fold increase in relative risk (RR) of admission to a pediatric intensive-care unit for mechanical ventilation (RR, 10.99 [95% confidence interval, 5.0-24.12]; P<.001, by Fisher exact test). Dual infection by hMPV and hRSV is associated with severe bronchiolitis.

Impetigo neonatorum associated with late onset group B streptococcal meningitis.

We present a case of nonbullous impetigo neonatorum associated with late onset group B streptococcal meningitis in a 12-day-old infant. Both skin lesions and meningitis resolved with antibiotic therapy. This is the first reported case of meningitis during the course of this skin disease.

Paediatric acute epiglottitis: not a disappearing entity.

OBJECTIVE: Paediatric epiglottitis is a serious, potentially life-threatening condition. Since the widespread introduction of the Haemophilus influenzae type b (Hib) conjugate vaccine in the UK in October 1992, there has been a dramatic reduction in its incidence. Vaccine failure is rare. The purpose of this study is to examine the failure rate of H. influenzae type b vaccine as measured by the number of cases of Haemophilus epiglottitis in fully vaccinated children presenting to a tertiary paediatric centre. A secondary aim is to provide a retrospective review of all cases of epiglottitis over a 13-year period. METHODS: A retrospective case-note review identifying all cases of epiglottitis presenting to Alder Hey Hospital was undertaken covering the time period December 1987-January 2001. Details of patient age, sex, source of referral, clinical presentation, management and complications along with microbiological and serological findings were obtained. There were 21 males and 19 females. The mean age was 36 months (range 6-125 months). A provisional diagnosis was made on the basis of the clinical features, confirmed by direct laryngoscopy in all but two cases and further supported in 28 cases by a positive blood culture. Of the 40 children presenting with epiglottitis, eight (20%) presented after the introduction of the Hib conjugate vaccine. H. influenzae antibody titres were measured both in the acute and convalescent phases of illness by the central Haemophilus Reference Unit in Oxford. RESULTS: We present the clinical features, management and complications of 40 cases of acute epiglottitis. H. influenzae was isolated from blood cultures in 28 cases (70%). In 12 of these cases, H. influenzae type b was identified, seven prior to 1993 and five thereafter. Four of these five cases presenting after introduction of the Hib vaccine were known to have been fully vaccinated. One child had a history of prematurity and serum immunoglobulin estimation was abnormally low in another child. Acute Hib antibody titre was less than 1 microg/ml in two of the three cases in which this was available. CONCLUSION: Whilst the incidence of Haemophilus type b epiglottitis has significantly diminished, vaccine failure does occur. We discuss the current understanding of clinical and immunological risk factors for vaccine failure and the significance of the Hib antibody titre. Further evaluation of vaccine failure would be of benefit. The series that we present highlights the importance of considering acute epiglottitis in the differential diagnosis of the child presenting with acute upper airway obstruction. This is particularly relevant when in future there will be fewer doctors familiar with the symptoms and signs of the disease.

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa.

Mapping an area at risk of epidemics of meningococcal meningitis in Africa has significant implications for their prevention and case treatment, through the targeted development of improved surveillance systems and control policies. Such an area was described using information obtained from published and unpublished reports of meningitis epidemics between 1980 and 1999 and cases of meningococcal disease reported by surveillance systems to WHO. The Sahel bore the greatest epidemic burden, with over two-thirds of documented outbreaks and high attack rates. In addition to those already in the Meningitis Belt, countries affected included Guinea-Bissau, Guinea, Côte d'Ivoire, Togo, the Central African Republic and Eritrea. Elsewhere epidemics were reported from a band of countries around the Rift Valley and Great Lakes regions extending as far south as Mozambique and from here west to Angola and Namibia in southern Africa. The cumulative pan-continental analysis provided evidence of an epidemic-susceptible area which extends beyond the region accepted as the Meningitis Belt and which, moreover, may be partially determined by the physical environment, as shown by a striking correspondence to the 300-1100-mm mean annual rainfall isohyets.

Detección de títulos de Antiestreptolisina o (AELO) en una población pediátrica y rural de Antioquia / Antistreptolysin O titre detection in a rural pediatric population

Introducción: la fiebre reumática, complicación no supurativa de la amigdalofaringitis causada por Streptococcus del Grupo A (SGA), es un problema de salud pública principalmente en niños de 6 a 15 años. 15 por ciento a 20 por ciento de la población es portadora del agente causal, lo cual es un factor importante de diseminación de la infección en comunidades. En Antioquia se reportan 800 – 1000 casos de pacientes con fiebre reumática al año, quienes consultan por presentar signos y síntomas sugestivos del diagnóstico, pero los casos cuya clínica es bizarra pasan desapercibidos agravando las secuelas. La detección de Antiestreptolisinas O revela la frecuencia de la infección por SGA en grupos de riesgo. Objetivos: determinar AELO en muestras de sangre tomadas en papel de filtro. Determinar la frecuencia de títulos de AELO en niños de 6 a 14 años. Metodología: se estudiaron 506 muestras de sangre en papel de filtro de niños de 6 a 14 años procedentes de diferentes regiones de Antioquia del banco de muestras del Instituto Colombiano de Medicina Tropical. Los títulos de AELO fueron medidos en el eluido de la muestra utilizando reactivos Difco. Resultados: de las 506 muestras estudiadas, 154 (30.4 por ciento) presentaron títulos de AELO ≥320, 71 (14 por ciento) tuvieron títulos ≥ 640. Discusión: la determinación de AELO en muestras de sangre en papel de filtro facilitan y disminuyen costos en estudios poblacionales conservando las características de la técnica. La frecuencia de títulos elevados de AELO en el grupo estudiantil revela que la infección SGA en Antioquia es importante, las complicaciones y secuelas permanecen desconocidas